Recent Updates
Recently added Catalysts

Long Chain Fatty Acid Oxidation Disorders: one US-listed biotech with a clinical-stage programme

Cardiovascular & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.5Buniverse median $1.20B
Allocated capital$488M$1.5B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank201/299crowding rank 207

Long Chain Fatty Acid Oxidation Disorders is uncontested. Ultragenyx Pharmaceutical (RARE) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Triheptanoin in phase 3.

There is no public comparable to price it against. RARE spreads its $1.5B market cap across 3 indications, so $488M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$488M of allocated capital sits in Long Chain Fatty Acid Oxidation Disorders, ranking it 201st of 299 indications by the money committed to it.

Companies developing drugs for Long Chain Fatty Acid Oxidation Disorders 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
RAREUltragenyx PharmaceuticalTriheptanoinPhase 31$1.5BNo3 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Long Chain Fatty Acid Oxidation Disorders counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Long Chain Fatty Acid Oxidation Disorders has one competitor and a median of $1.5B.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

Chronic Idiopathic Constipation1 company · $462M · median $924MUncontestedGestational Diabetes1 company · $424M · median $1.3BUncontestedChronic Kidney Disease Stage 3 and 41 company · $601M · median $1.2BUncontestedProteinuric Kidney Disease1 company · $719M · median $1.4BUncontestedGout1 company · $211M · median $211MUncontestedArrhythmogenic Right Ventricular Cardiomyopathy2 companies · $210M · median $277MOrphan cornerAnemia Associated With Chronic Kidney Disease1 company · $180M · median $1.6BUncontestedVenous Leg Ulcers1 company · $170M · median $170MUncontested

Long Chain Fatty Acid Oxidation Disorders pipeline questions

Which biotech companies are developing drugs for Long Chain Fatty Acid Oxidation Disorders?

Ultragenyx Pharmaceutical (RARE, Triheptanoin, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Long Chain Fatty Acid Oxidation Disorders.

How advanced is the Long Chain Fatty Acid Oxidation Disorders pipeline?

Of the 1 clinical-stage programme in Long Chain Fatty Acid Oxidation Disorders, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Long Chain Fatty Acid Oxidation Disorders?

No. RARE is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Long Chain Fatty Acid Oxidation Disorders, which is why the indication is classified as uncontested.

When is the next Long Chain Fatty Acid Oxidation Disorders catalyst?

The next dated catalyst in Long Chain Fatty Acid Oxidation Disorders is RARE on 30 Sep 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map